021-51111890
购物车（）
sales@molnova.cn
DAMGO (TFA)
CAS No. 950492-85-0
DAMGO (TFA) ( —— )
产品货号. M30306 CAS No. 950492-85-0
DAMGO is a selective peptide agonist of the μ-opioid receptor .
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥778 | 有现货 |
|
| 10MG | ￥1340 | 有现货 |
|
| 25MG | ￥2781 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称DAMGO (TFA)
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述DAMGO is a selective peptide agonist of the μ-opioid receptor .
-
产品描述DAMGO is a selective peptide agonist of the μ-opioid receptor .
-
体外实验DAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression.DAMGO (1 μM) TFA effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R I Na), i.e. PGE 2 (1 μM) can increase the TTX-R I Na peak by 103 % compared to 24.9 % with the addition of DAMGO.
-
体内实验DAMGO (i.v., 0.5-2 mg/kg) TFA can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect.
-
同义词——
-
通路Endocrinology/Hormones
-
靶点Opioid Receptor
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number950492-85-0
-
分子量627.61
-
分子式C28H36F3N5O8
-
纯度>98% (HPLC)
-
溶解度H2O : 125 mg/mL (199.17 mM; Need ultrasonic)
-
SMILES——
-
化学全称Sequence:Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.
产品手册
关联产品
-
AT-121
AT-121 是一种双功能的 nociception 和 mu 阿片受体 (mu opioid receptor) 激动剂，Ki 值分别为 3.67 和 16.49 nM。AT-121 是一种安全、无成瘾性的缓解疼痛药，具有抗伤害和止痛作用。
-
Docusate sodium
Docusate Sodium (Dioctyl sulfosuccinate sodium salt) 是一种可用于便秘研究的化合物。
-
Hemorphin-7
Hemorphin-7 binds to the angiotensin IV receptor, triggering multiple effects including cellular proliferation and memory enhancement. Hemorphins are endogenous peptides belonging to the family of atypical opioid peptides released from hydrolyzed hemoglobin. Hemorphin-7 is investigated as a potential biomarker for breast cancer.
